Literature DB >> 2007212

Endocrine crises. Hyperkalemia.

M E Williams1.   

Abstract

Clinical disorders causing hyperkalemia require a basic understanding of normal K homeostasis, which consists of external and internal K balances. The kidney is predominant in maintaining the external balance of K, and a number of mechanisms exist to provide a renal adaptation to defend against K excess. Likewise, several factors are known to modulate internal K balance--i.e., its distribution within the body. Some of these factors may provide defense against hyperkalemia before the kidneys have time to adapt. Potassium retention by the kidney causes hyperkalemia when renal failure is advanced, or earlier in the face of impaired tubular function in a variety of disorders. Hyperkalemia out of proportion to loss of renal function also occurs in the syndrome of hyporeninemic hypoaldosteronism. Drug-induced hyperkalemia is increasingly common and usually is caused by nonsteroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, cyclosporine, or K-sparing diuretics. Clinical disorders of internal K imbalance include diabetes mellitus, systemic acidosis, and use of beta-blockers. Hyperkalemia is usually asymptomatic, but the danger of cardiac arrest or arrhythmia in severe hyperkalemia forces prompt clinical attention. Available treatment choices include agents that antagonize the effect of K on membrane potentials, redistribute it internally into cells, and remove it altogether from the body. The diagnostic work-up can then proceed, first by distinguishing renal and extrarenal causes, then by examining the roles of specific factors outlined in the section on normal K homeostasis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007212

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  9 in total

1.  The positive predictive value of a hyperkalemia diagnosis in automated health care data.

Authors:  Marsha A Raebel; Michael L Smith; Gwyn Saylor; Leslie A Wright; Craig Cheetham; Christopher M Blanchette; Stanley Xu
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-11       Impact factor: 2.890

2.  Acute Renal Failure with Hyperkalemia Presenting as Recurrent Syncope.

Authors:  R Bhardwaj
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease.

Authors:  Georges N Nakhoul; Haiquan Huang; Susana Arrigain; Stacey E Jolly; Jesse D Schold; Joseph V Nally; Sankar D Navaneethan
Journal:  Am J Nephrol       Date:  2015-07-25       Impact factor: 3.754

4.  Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

Authors:  Martin Chaitman; Deepali Dixit; Mary Barna Bridgeman
Journal:  P T       Date:  2016-01

5.  The frequency of hyperkalemia and its significance in chronic kidney disease.

Authors:  Lisa M Einhorn; Min Zhan; Van Doren Hsu; Lori D Walker; Maureen F Moen; Stephen L Seliger; Matthew R Weir; Jeffrey C Fink
Journal:  Arch Intern Med       Date:  2009-06-22

6.  Mild hyperkalemia and low eGFR a tedious recipe for cardiac disaster in the elderly: an unusual reversible cause of syncope and heart block.

Authors:  Emad F Aziz; Fahad Javed; Aleksandr Korniyenko; Balaji Pratap; Juan Pablo Cordova; Carlos L Alviar; Eyal Herzog
Journal:  Heart Int       Date:  2011-10-26

7.  Clinical safety and outcomes of glucagon use during endoscopic retrograde cholangiopancreatography (ERCP).

Authors:  Abhilash Perisetti; Hemant Goyal; Neil Sharma
Journal:  Endosc Int Open       Date:  2022-04-14

8.  The Effect of Alcoholic Extract of Anabasis syriaca Iljin on Biochemical and Histological Parameters in Rats.

Authors:  Suad M Kloub; Saleem A Banihani; Omar M Atrooz; Wael M Hananeh
Journal:  J Toxicol       Date:  2022-03-24

9.  The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease.

Authors:  Marc Evans; Eirini Palaka; Hans Furuland; Hayley Bennett; Cecilia Linde; Lei Qin; Phil McEwan; Ameet Bakhai
Journal:  BMC Nephrol       Date:  2019-01-31       Impact factor: 2.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.